PHARMACY

Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar

BY David Salazar
INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
 
The Food and Drug Administration approved Basaglar in December 2015 as a long-acting insulin to control high blood sugar in adults and children with Type 1 diabetes and adults with Type 2 diabetes. It is not indicated to treat diabetic ketoacidosis, nor should it be used during hypoglycemic episodes. 
 
“Lilly and Boehringer Ingelheim are proud to bring another proven effective diabetes treatment choice to people who may need a long-acting insulin to help control their blood sugar,” Lilly Diabetes VP global medical affairs Dr. David Kendall said. “We know that starting insulin can be a challenging experience for some people with type 2 diabetes. As part of our continuing commitment to the diabetes community, we are expanding our educational resources.”
 
The companies will offer a Basaglar savings card for eligible patients, and it will provide bilingual resources, including a mobile app to provide patients an interactive experience to guide them through injection using the Basaglar KwikPen, injection demo kits and educational video access. 
 
Basaglar will be available by prescription from retail and mail-order pharmacies in the U.S., and the top three pharmacy benefit managers have selected it for their formularies, the companies said.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA approves Pfizer’s eczema treatment Eucrisa

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced its approval of Pfizer’s Eucrisa (crisaborole). The ointment is indicated to treat mild to moderate eczema in patients two years of age and older. 
 
“The approval of Eucrisa is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” Pfizer Innovative Health group president Albert Bourla said. “This is also an important milestone for Pfizer as we continue to build on our heritage in Inflammation and Immunology by offering innovative treatment options to patients who need them.”
 
“Today’s approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis,” said Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.
 
The drug was brought into Pfizer’s portfolio in May with its $5.2 billion acquisition of Anacor Pharmaceuticals. In May, the company said that it projected Eucrisa to potentially bring in $2 billion or more once it received approval. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

South Florida’s University of Miami Health System signs Walgreens collaboration agreement

BY Michael Johnsen

DEERFIELD, Ill. – Walgreens and the University of Miami Health System on Wednesday announced a collaboration focused on delivering coordinated clinical care and pharmacy excellence to patients across South Florida.

“Walgreens has been a trusted provider of pharmacy and other health care services to South Florida residents and those within the UM community for decades,” said Brad Fluegel, SVP and chief healthcare commercial market development officer at Walgreens. “This is a tremendous opportunity to work closely with the UM Health System to help ensure a true continuum of care, with our pharmacists playing an integral role as part of patients’ care teams. Forming deeper and more collaborative relationships with health systems is one of the ways in which we’re responding to the changing needs of both patients and our health care system.”

“This collaboration is an important step in UHealth’s commitment to improving the health of our community and access to our high quality clinicians,” stated Steven Altschuler, CEO of the University of Miami Health System. “We will provide a seamless and integrated health care experience for our patients regardless of where they receive their care across our University of Miami Health System.”

As part of the agreement, UHealth – the University of Miami Health System, will manage and provide all clinical services at 17 retail clinics within Walgreens stores in South Florida, including Miami-Dade, Broward and Palm Beach counties.
 
In addition, Walgreens will soon open pharmacies at three University of Miami Health System facilities, as its exclusive retail pharmacy provider. The new pharmacy at The Lennar Foundation Medical Center, UHealth’s state-of-the-art facility in Coral Gables, is planned to open Dec. 19. Walgreens retail pharmacies at Sylvester Comprehensive Cancer Center and University of Miami Hospital are expected to open in January.

Walgreens will also provide 90-day retail prescription benefits and specialty pharmacy services for the University’s employees and their families.

The 17 existing Walgreens Healthcare Clinics are planned to transition to the University of Miami Health System in the spring of 2017, at which time the clinics will become an extension of the UM Health System and be named UHealth Clinic – University of Miami Health System at Walgreens. Walgreens will continue to manage the retail clinics until that time.
 
UHealth Clinic at Walgreens will give consumers improved access to the transformative, research-based, personalized care provided by the University of Miami Health System. Staffed by UHealth’s expertly-trained nurse practitioners, the UHealth Clinic at Walgreens locations will operate seven days a week, including evenings, giving patients the option to receive a variety of health care services with or without an appointment.
 
Patients across South Florida will have access to affordable and conveniently located clinics for treating common illnesses and injuries as well as for follow up care for chronic diseases when appropriate.

Walgreens and the University of Miami Health System will also form a joint council to share best practices and experiences that aim to improve patient care, quality and satisfaction while reducing health care costs.
 
“Building from this start, the University and Walgreens intend to explore new approaches to further extend access to routine and specialty care, to improve patient health through enhanced pharmacy services, and to utilize innovative ways to reach patients when and where they would benefit,” added John Sory, UHealth’s chief executive of the UHealth Regional Alliance.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?